Exposure of hematologic cancer cell lines and patient-derived cell samples to various HDACi resulted in a significant caspase-independent inhibition of protein PARylation, mainly catalyzed by PARP1. Here, PARP1 is linked to hematopoietic and lymphoid cell neoplasm.